Extraordinary: bear and bull market all in one

It is the era of superlatives, the most frequent being “unprecedented”. The term is unavoidable and, I suspect, carries a level of unease only comparable to what many of our grandparents must have felt following the declarations of war that heralded World War II. Except that the state of emergency we find ourselves in now is far harder to grasp than a conventional conflict situation.

Perhaps this is why this month stock, bond, currency, commodity and all other traded asset markets which in aggregate we refer to a capital markets have displayed quite extraordinary dynamics. The week’s headline is that over the course of March 2020 we experienced both bear market conditions due to falls in excess of 20%, but also bull market conditions with some stock markets this week rising in excess of 20% over three successive days of recovery. On Friday the rebound ended, and the week’s recovery now looks very much like the sort of short-term bounce common during bear market periods. For more on the subject of bear market dynamics, please look at the article in the downloadable document titled: ‘The anatomy of a bear market’

Tatton Asset Management PLC (LON:TAM) offers a range of services to directly authorised financial advisers in the United Kingdom. The Company provides on-platform portfolio management, regulatory, compliance, and business consulting services. 

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Tatton Asset Management Plc

    More articles like this

    boohoo Plc

    boohoo group total group sales +61% since FY2020

    boohoo group plc (LON:BOO) have today published final results for the year ended 28th February 2022. Investing for the future ·    Significantly increased market share in the UK and US since FY2020. Total group sales +61% since FY2020 ·    Extended

    Fintel plc

    Fintel Plc appoint Phil Smith as Non-Executive Director

    Fintel plc (LON: FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has announced the appointment of Phil Smith as Independent Non-Executive Director with immediate effect. Following a robust process led

    Pendragon plc

    Pendragon underlying Profit before Tax of £18.7m, up 73.1%

    Pendragon plc (LON:PDG) has announced its interim management statement. This Interim Management Statement covers the period from 1 January 2022 to 31 March 2022.  Unless otherwise stated, figures quoted in this statement are for the three

    SpaceandPeople returns to profit

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued full

    SpaceandPeople back into profit and positive earnings per share

    SpaceandPeople plc (LON:SAL) the retail, promotional and brand experience specialist, has announced its final results for the year ended 31 December 2021.   Financial Highlights ·       Revenue of £4.0 million (2020: £2.8 million and 2019: £7.7 million) ·       Operating profit of

    tinyBuild plc

    tinyBuild acquihires development studio Demagic Games

    tinyBuild plc (LON:TBLD), a premium video games publisher and developer with global operations, has announced the acquihire of Demagic Games, a development studio with 23 staff[1] currently based in Ukraine and Russia. The Company has been working

    Vertu Motors Plc

    Vertu Motors share buyback programme update

    Vertu Motors plc (LON: VTU) has announced that on 07 April 2022, it purchased 201,999 ordinary shares of 10p each in the Company on the London Stock Exchange, pursuant to the share buyback programme that was announced on 2nd March 2022 as

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer